MDXG

#2752
MiMedx Group, Inc - Common Stock
4.4 3 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
4.43
4.43
Jahresspanne
3.03
7.97
Tagesänderung
-2.64%
Monatliche Änderung
+3.75%
6 month change
-7.13%
Jahresänderung
-37.61%
Vorheriger Schlusskurs
4.5 5
Open
4.4 3
Tief
4.4 3
Hoch
4.4 3
Volumen
51
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
MIMEDX GROUP, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
MIMEDX GROUP, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
MIMEDX GROUP, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MIMEDX GROUP, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MIMEDX GROUP, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MIMEDX GROUP, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MIMEDX GROUP, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MIMEDX GROUP, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MIMEDX GROUP, INC. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
MIMEDX GROUP, INC. annual report, FY2025
10-K

MIMEDX GROUP, INC. current report, 20 November 2020

Full document

Business Context and Reporting Period

MiMedx Group, Inc. (MDXG) filed a Form 8-K Current Report on November 20, 2020. The filing serves as a Regulation FD disclosure regarding the Company's annual meeting held on the same date. The registrant is incorporated in Florida and trades on The Nasdaq Stock Market LLC.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and strategic updates rather than financial performance data.

Material Changes and Corporate Events

  • Annual Meeting: The Company hosted its annual meeting on November 20, 2020, at 10:00 a.m. Eastern time.
  • Management Presentations:
    • Timothy R. Wright (CEO) presented an overview of the Company.
    • Rohit Kashyap, Ph.D. (EVP, Chief Commercial Officer) and Robert B. Stein, M.D., Ph.D. (EVP, R&D) presented on commercial and R&D initiatives.
  • Strategic Focus: Presentations included updates on estimated potential market sizes for future products intended to treat knee osteoarthritis pain.

Guidance, Outlook, and Risks

The filing includes a slide presentation (Exhibit 99.1) containing forward-looking information regarding market sizes and product initiatives. The Company explicitly disclaims any obligation to update this information in the future. Additionally, the Company disclaims any inference regarding the materiality of the information furnished under Item 7.01. Information on the Company's website is not incorporated by reference into this filing.

Investor Verification Checklist

  • Review Exhibit 99.1 (Slide presentation dated November 20, 2020) for specific details on R&D initiatives and market size estimates.
  • Verify the status of products intended to treat knee osteoarthritis pain as discussed by management.
  • Consult the Company's website (www.mimedx.com) for the presentation materials, noting that website content is not incorporated by reference into this 8-K.
  • Check subsequent filings for any updates to the forward-looking statements made during the annual meeting.

Nachrichten